These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24113523)

  • 1. Chlorbipram: a novel PDE4 inhibitor with improved safety as a potential antidepressant and cognitive enhancer.
    Zhang MZ; Zhou ZZ; Yuan X; Cheng YF; Bi BT; Gong MF; Chen YP; Xu JP
    Eur J Pharmacol; 2013 Dec; 721(1-3):56-63. PubMed ID: 24113523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA interference-mediated phosphodiesterase 4D splice variants knock-down in the prefrontal cortex produces antidepressant-like and cognition-enhancing effects.
    Wang ZZ; Zhang Y; Liu YQ; Zhao N; Zhang YZ; Yuan L; An L; Li J; Wang XY; Qin JJ; Wilson SP; O'Donnell JM; Zhang HT; Li YF
    Br J Pharmacol; 2013 Feb; 168(4):1001-14. PubMed ID: 23003922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme.
    Zhang HT; Huang Y; Jin SL; Frith SA; Suvarna N; Conti M; O'Donnell JM
    Neuropsychopharmacology; 2002 Oct; 27(4):587-95. PubMed ID: 12377395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of p38 and JNK Signaling Pathways.
    Yu H; Zou Z; Zhang X; Peng W; Chen C; Ye Y; Xu J; Wang H
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29419799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.
    Zhang HT; Zhao Y; Huang Y; Deng C; Hopper AT; De Vivo M; Rose GM; O'Donnell JM
    Psychopharmacology (Berl); 2006 Jun; 186(2):209-17. PubMed ID: 16586089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of ethanol abstinence-induced anxiety- and depressive-like behavior by the phosphodiesterase-4 inhibitor rolipram in rodents.
    Gong MF; Wen RT; Xu Y; Pan JC; Fei N; Zhou YM; Xu JP; Liang JH; Zhang HT
    Psychopharmacology (Berl); 2017 Oct; 234(20):3143-3151. PubMed ID: 28748375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
    Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
    Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses.
    Zhou ZZ; Cheng YF; Zou ZQ; Ge BC; Yu H; Huang C; Wang HT; Yang XM; Xu JP
    ACS Chem Neurosci; 2017 Jan; 8(1):135-146. PubMed ID: 27690383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant-like effect of etazolate, a cyclic nucleotide phosphodiesterase 4 inhibitor--an approach using rodent behavioral antidepressant tests battery.
    Jindal A; Mahesh R; Gautam B; Bhatt S; Pandey D
    Eur J Pharmacol; 2012 Aug; 689(1-3):125-31. PubMed ID: 22698578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
    Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
    J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
    McDonough W; Aragon IV; Rich J; Murphy JM; Abou Saleh L; Boyd A; Koloteva A; Richter W
    FASEB J; 2020 Sep; 34(9):12533-12548. PubMed ID: 32738081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the emetic potential of PDE4 inhibitors in rats.
    Robichaud A; Savoie C; Stamatiou PB; Lachance N; Jolicoeur P; Rasori R; Chan CC
    Br J Pharmacol; 2002 Jan; 135(1):113-8. PubMed ID: 11786486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
    Rutter AR; Poffe A; Cavallini P; Davis TG; Schneck J; Negri M; Vicentini E; Montanari D; Arban R; Gray FA; Davies CH; Wren PB
    J Pharmacol Exp Ther; 2014 Jul; 350(1):153-63. PubMed ID: 24784567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of a novel, orally active PDE4 inhibitor.
    Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
    Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term cognitive dysfunction in the rat following docetaxel treatment is ameliorated by the phosphodiesterase-4 inhibitor, rolipram.
    Callaghan CK; O'Mara SM
    Behav Brain Res; 2015 Sep; 290():84-9. PubMed ID: 25940764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
    Ishii N; Shirato M; Wakita H; Miyazaki K; Takase Y; Asano O; Kusano K; Yamamoto E; Inoue C; Hishinuma I
    J Pharmacol Exp Ther; 2013 Jul; 346(1):105-12. PubMed ID: 23674603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors.
    Pieretti S; Dominici L; Di Giannuario A; Cesari N; Dal Piaz V
    Life Sci; 2006 Jul; 79(8):791-800. PubMed ID: 16546218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.
    Tralau-Stewart CJ; Williamson RA; Nials AT; Gascoigne M; Dawson J; Hart GJ; Angell AD; Solanke YE; Lucas FS; Wiseman J; Ward P; Ranshaw LE; Knowles RG
    J Pharmacol Exp Ther; 2011 Apr; 337(1):145-54. PubMed ID: 21205923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of the rat model of conditioned gaping to detect nausea produced by rolipram, a phosphodiesterase-4 (PDE4) inhibitor.
    Rock EM; Benzaquen J; Limebeer CL; Parker LA
    Pharmacol Biochem Behav; 2009 Feb; 91(4):537-41. PubMed ID: 18835293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of type 4 cAMP-phosphodiesterases (PDE4s) in mice induces hypothermia via effects on behavioral and central autonomous thermoregulation.
    McDonough W; Rich J; Aragon IV; Abou Saleh L; Boyd A; Richter A; Koloteva A; Richter W
    Biochem Pharmacol; 2020 Oct; 180():114158. PubMed ID: 32702371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.